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2• Analytical Comparability to accelerate 
transition from launch to larger facility 
• Modernization of Assay Procedures 
for Legacy Vaccines 
Outline
3Gardasil®: Merck’s Recombinant 
Quadrivalent HPV Vaccine
• L1 major capsid proteins (Types 6,11,16,18) 
each self-assemble into virus-like particles (VLPs)
• VLPs produced intracellularly 
in Saccharomyces cerevisiae
• VLPs do not contain viral DNA 
(non-infectious)
Type 18 VLP• Approved world wide in 2006 
to prevent cervical cancer and warts
4What Did We Know Early On?
• Animal models
• Early dose ranging looking at antibody 
response 
• No accepted correlate
• Do we have a product?
• What to test in Phase III
• Should we invest in a factory?
• How could we compress the timeline?
5How Do We Show Cancer Efficacy?
0 to 1 Year 0 to 5 Years Up to 20 Years
Initial 
HPV
Infection
Continuing 
Infection
CIN 
2/3
Cervical 
Cancer
CIN 1
Cleared HPV Infection
Definitive 
Efficacy
6Manufacturing Strategy 
What are the constraints? 
• Clinical studies would take many years
• Proof of concept studies underway
• Early data looks promising
• Need final manufacturing facility for Phase III and 
manufacturing consistency lots 
• Marketing expectations are high
• Properly sized facility years to build
• Proposal to build launch facility (New Products Suite) 
• Quicker to build but limited capacity
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7PV/CC Clinical File/WAIT
Approval/ 
LAUNCH
Build Full-scale
Build Mid-scale
Comparability
POC
PV/CC Clinical File/WAIT
Approval/ 
LAUNCH
$$$$$
$$
$$$$$
Build Mid-scale
GAIN
GAP
Build Full-scale PV File/wait
Approval/ 
LAUNCH
gap
Minimizes gap
Provides world-wide
supply ASAP
GAIN brings a cervical cancer 
vaccine to market ASAP
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Building a mid-scale facility 
can decrease time to launch
Moderately-scaled facility allows for a GAIN
 
in time to 
filing/launch, but limits supply
Filling the GAP
 
in supply awaits licensure of full-scale 
facility
Build Full-scale? ?PV/CC Clinical File/WAIT
Approval/ 
LAUNCH
PV/CC Clinical File/WAIT
Approval/ 
LAUNCH
8• Used for “specified” or “well-characterized” 
biologic products such as MABs. 
• Facilitate approval of process changes without a 
clinical trial 
• Prospective protocol for documenting process 
changes 
• Can’t always state if a change matters.
• Focused testing rather than testing to infinity
• Testing strategy validated with known samples 
with known differences in performance 
’
Analytical Comparability
9HPV-18 VLP Image Reconstruction 
(20-Å Resolution False-color Image, Cryo-TEM)
IgG Immunoglobin
Courtesy of 
NanoImaging Systems
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• Ideal case: Have two samples:
– Differ in characterization data
– Differ in process source
– Differ in “potency” e.g. mouse
– Differ in clinical performance (!!!!!)
• Will validate that assays are sensitive to significant 
process changes. 
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Comparability Strategy
11
Structural Model of HPV VLP
Virus-Like Particle
(~20,000 kDa)
L1 Capsomere
(~280 kDa)
5 ×
 
L1
(Atomic force microscopy
image of a single VLP)
L1 protein
(55 or 57 kDa)
(Crystal structure coordinates
courtesy of Prof. S. C. Harrison,
Harvard University)
~ 3 nm ~ 10 nm
~ 60 nm
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GARDASIL Analytical Characterization
Adjuvant-Antigen 
Complex
DLS, DSC, IVRP & 
IC50
3° and 4° Structure
DLS, IC50 , Relative Antigenicity, 
Free Thiols in Native Form &  L1- 
Oligomer, Cryo-EM
2° Structure
CD & FT-IR
1° Structure
Peptide Map,
Purity, Integrity, 
Deamidation
& Free Thiols in 
Denatured Form
Amino Acid 
Sequence
Assembly
Disassembly
Adsorptionα-Helix
β-Sheet
Aluminum
Adjuvant
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Manufacturing Process For Early Studies
Cell Thaw/Disruption
Nuclease Treatment
Microfiltration
Capture Chromatography
Polishing Chromatography
Ultrafiltration
Sterile Filtration
Alum Adsorption
Fermentation/Harvest
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Prelicensure Process Change
• Introduce disassembly/reassembly before 
Phase III and Process Validation 
• Part of final manufacturing process
• More stable product
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Final Manufacturing Process
Cell Thaw/Disruption
Nuclease Treatment
Microfiltration
Capture Chromatography
Polishing Chromatography
Ultrafiltration
Sterile Filtration
Alum Adsorption
Fermentation/Harvest
VLP Dis/reassembly
16
VLP Characterization by Atomic Force and 
Transmission Electron Microscopy
FAP INT
TEM Images of HPV-16
FAP INT
Morley, Y. Wang & Shi
Relative Antigenicity Comparison between Non-
Reassembled and Reassembled HPV16 VLP Samples
• Antigenicity defined by neutralizing antibody is enhanced.
• Antigenicity defined by antibody against linear epitope is reduced.
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18Ln (IVRP:Protein)
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Disassembled/Reassembled VLP 
Correlation of IVRP and Immunogenicity 
Type 16
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Phase III Efficacy
Study Protocol 007
GMT ~ 3500
HPV 16 Efficacy
Study Protocol 005
GMT 1500-2000
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Comparability: 
Differential Scanning Calorimetry
• Measures the change in 
the heat capacity during 
thermal unfolding.
• VLPs adsorbed to 
aluminum adjuvant.
• Distinguishes INT & FAP 
samples.
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• Ideal case: Have two samples:
– Differ in characterization data
– Differ in process source
– Differ in “potency” e.g. mouse
– Differ in clinical performance (!!!!!)
• Will validate that assays are sensitive to significant 
process changes. 
• Criteria met by unassembled/reassembled 
product pair for Type 16 
• Concept applied to other types (Type 18 not 
Reassembled) 
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Comparability Strategy
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• New Product Suite constructed
• Process validation completed
• Phase III and clinical consistency lots 
manufactured 
• Facility operated during clinical studies 
and agency review to build inventory 
• Extensive characterization testing applied 
to lots made in New Product Facility 
Manufacturing Strategy
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• Clinical  studies completed 
• BLA filed
• New full scale factory completed
• PV lots completed in new facility
Manufacturing Strategy (Ctd)
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How to Claim Comparability ?
Two Parts to Comparability
?Demonstrate Process Comparability
?Demonstrate Product Comparability
ili
ili
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Method HPV6 HPV11 HPV16 HPV18
Release - Potency
Release – Purity & 
Integrity
Mouse Potency
IC50
Rel. Antigen.
DSC
DLS
Free Thiols
Oligomer
Deamidation
Weighting
• Monitor clinically-relevant structural features that are
desirable properties of the product.
• Emphasis on release assays & epitope structure
(conformation) during manufacture & storage.
Analytical Matrix for Comparability
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Limits
Limits prospectively established to define potential 
deviations from comparability 
?Provides rigor and credibility
Two types of limits
?Acceptance limits = deviation generally means 
failure to demonstrate comparability
?Alert limits = deviation results in investigation, but 
not deemed a failure a priori
?Limits must be sufficiently rigorous but not so 
tight as to cause “nuisance alarms”
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Limits:  Product Characterization
Acceptance and Alert limits
?Release tests
?Process Validation CQAs:  impurities
Alert limits only
?Characterization tests
Qualitative comparisons
?Some Characterization tests: profiles for 
intermediate product stability, CD, FTIR
l
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VLP Size Distribution Characterization by DLS
0
2 0
4 0
6 0
8 0
1 0 0
0
2 0
4 0
6 0
8 0
1 0 0
0
2 0
4 0
6 0
8 0
1 0 0
0
2 0
4 0
6 0
8 0
1 0 0
Type 6
Type 11
Type 16
Type 18
H
y
d
r
o
d
y
n
a
m
i
c
 
D
i
a
m
e
t
e
r
(
n
m
)
H
y
d
r
o
d
y
n
a
m
i
c
 
D
i
a
m
e
t
e
r
 
(
n
m
)
0
20
40
60
80
100
Type 16
Different Full-Scale Production Lots
28
Plan Ahead to Manage Deviations
Resources – especially in the lab !
Purification in launch and new facility performed 
using same inputs to allow direct comparison 
(“sister lots”) 
?Same fermentation cell paste input
?Same lot of chromatography resins
Some analytical tests had very limited history
? Include samples from Phase III lots in the same 
assay run as the new facility lot
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Results - Analytical Comparability 
(Drug Substance) 
Method HPV6 HPV11 HPV16 HPV18
Release - Potency
Release – Purity & 
Integrity
Mouse Potency
IC50
Rel. Antigen.
DSC
DLS
Free Thiols
Oligomer
Deamidation
No Excursions
Alert Limit Excursion
Acceptance Limit Excursion
Weighting
? All parameters within Acceptance Limitsll  i i   i i
? 3 excursions of  Alert Limits investigated i    l  i i  i i
30
Results - Analytical Comparability
?All parameters within Acceptance Limits
? 3 excursions of  Alert Limits investigated
?New facility approved world wide
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?
PV/CC Clinical File/WAIT
Approval/ 
LAUNCHGO
Build Full-scale
Build Mid-scale
POC
$$$$$
$$
$$$$$
Build Mid-scale
GAIN
GAP
Build Full-scale PV File/wait
Approval/ 
LAUNCH
gap
GAIN brings a cervical cancer 
vaccine to market ASAP
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Building a mid-scale facility 
can decrease time to launch
Build Full-scale? PV/CC Clinical File/WAIT
Approval/ 
LAUNCH
PV/CC Clinical File/WAIT
Approval/ 
LAUNCH
PV/CC Clinical File/WAIT
Approval/ 
LAUNCH
minimizes gapComparability
process/analytical
& provides world-wide
supply ASAP
GAIN
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Summary
?Merck leveraged comparability to accelerate 
licensure of larger-scale facility meeting market 
demand.
? A modestly scaled purification facility was used to supply
Phase III and launch material
? A larger facility was required to meet expected demand
?Analytical data confirmed comparability of product from both       
facilities 
?A comprehensive analytical characterization package is 
critical to managing process changes in the development 
cycle for a vaccine.
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Modernization of Analytical 
Methods 
34
Process vs Analytical Changes
• Many vaccines (and Biologics) were licensed 
years ago with older technology 
• Process changes are well accepted in the 
Biotechnology Industry 
• What about changes in Analytical Methods?
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Process Changes
• Numerous Major Process changes have been 
implemented throughout the years 
– Plasma derived to r-Hepatitis B
– Whole cell pertussis to acellular
– Required extensive clinical trials to assure safety 
and efficacy 
• New Facilities, scale up and other process 
changes are common 
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Process Changes
• Process changes are well accepted in the 
Biotechnology Industry 
• Process changes are forward looking ie the 
new lots are distinct from the older process 
lots 
• Release and distribution are unique for new 
process lots 
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Why modernize Analytical 
Methods? 
• Vendors discontinue instrument or reagents
• Improvement in Robustness in existing assay
– New Format
– Automation vs manual (different philosophy)
– More reliable technology
• Agencies encouraging application of modern 
methods 
• Recent FDA Draft Guidance Document on 
Process Validation – “Continued Process 
Verification” 
i l i il
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Why modernize Analytical 
Methods? 
• New technology can be more precise and 
more efficient 
• Competitive newer or second generation 
products bring on newer methods 
• New and more precise tools to monitor 
existing processes and process 
improvements 
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What are the Barriers to 
implementing New Analytical 
Methods? 
• Will detect new impurities or residuals which 
were already present 
• Concern on looking back
• Difficulty to get concordance data between 
imprecise and more precise assays. 
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Modern “purity” Methods
• New methods like HPLC or CZE have higher 
resolution and show the presence of new 
impurities not seen before 
• Less of an issue as long as samples of older 
clinical lots have same components 
• Keep your PV samples!!!
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Issues on Implementation of 
Improved Assay Technology 
• New methods might have higher precision than older 
cellular and in vivo based potency methods 
• Many potency assays (eg flu, D, T, Pertussis) were 
originally validated years ago and might have been 
animal based and quite variable 
• How do you correlate a new more precise potency 
assay to a highly variable assay? 
• How do you set specs for a new potency assay?
• Will the new specs applied to older lots?
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Hypothetical Results 
Old vs New Assay 
Old Assay
Different lots New Assay 
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Tight Process
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Issues on Implementation of 
Improved Assay Technology 
• Must equivalency be demonstrated?
• Should the new assay give identical results?
• If the older assay had high variability, difficult 
to demonstrate equivalence 
• Target should be a “superior” assay
– Higher precision
– Easier to run
– Automatable
– Animal sparing
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Issues on Implementation of 
Improved Assay Technology 
• Concordance vs offset of assay in 
comparative studies 
• Characterize difference
• Pay attention to sample handling and 
container issues 
• Seek agency agreement on statistical 
approach 
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Proposal
• Define principles for dealing with mismatch between 
highly variable and tighter assay technologies 
• Consensus on assay concordance around the 
industry: new and old assays are not going to be 
concordant across technologies that are 20-30 years 
apart in sensitivity and accuracy 
• Work through the implementation of new assay 
methodology thru: 
– Further discussions with agencies on issue
– Joint Industry – Agency groups
– PDA?
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